• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Virpax reports positive non-human study results for topical spray film that treats chronic pain

December 8, 2021 By Sean Whooley

VirpaxVirpax Pharmaceuticals (NSDQ:VRPX) today reported positive results from a study of its Epoladerm treatment for chronic pain management.

Berwyn, Pennsylvania-based Virpax designed Epoladerm, one of its lead investigational products, for managing pain associated with osteoarthritis of the knee.

According to a news release, the company reported positive results following the completion of a toxicology and pharmacokinetic study designed to support clinical trials with Epoladerm.

Charles River Laboratories, having been engaged by Virpax to perform FDA-required pre-clinical studies, completed a single-dose pharmacokinetic study of dermal administration of Epoladerm, delivered through a pre-filled device as a topical spray film.

Virpax’s proprietary technology acts as an aerosol canister for the application of the spray film to the knee. The company touts the resulting film as thinner than a standard liquid bandage, with clear coating upon application to the knee, while it dries fast.

Charles River Laboratories’ study had Epoladerm administrated in minipigs as part of the investigational new drug (IND) application-enabling trials, with delivery well-tolerated in all minipigs. There were no treatment-related clinical observations, changes in body weight or dermal irritation.

All Epoladerm-treated animals had plasma levels of Epoladerm confirming transdermal absorption, with the maximum plasma concentration reached at four hours post-dose, while plasma Epoladerm remained at 24 hours post-dose for all animals.

Virpax said it expects the data to strengthen its IND filing with the FDA in advance of its anticipated commencement of first-in-human clinical trials.

“This is an important step in the development of Epoladerm and further prepares us for expected clinical trials,” Virpax Chairman & CEO Anthony P. Mack said. “The results of this study underscore the safety of our spray film technology.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals Tagged With: Charles River Laboratories, Virpax Pharmaceuticals

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS